|
|
Project TASS |
In the TASS project, AnaMar is developing orally bioavailable compounds for the treatment of rheumatoid arthritis (RA), osteoarthritis (OA) and inflammatory pain. Currently, there are no drugs on the market using 5-HT2 receptor antagonists for the chosen indications, which represents a unique opportunity. The IP situation is also strong, with patents granted in Europe and the US. |
Therapeutic area: |
| Rheumatoid arthritis, other inflammatory diseases and inflammatory pain |
Stage of development: |
|
|
Mechanism of action: |
| 5-HT2 antagonism, thereby leading to a reduction in inflammatory cytokine production and a reduction of inflammatory pain. |
Competitive advantages: |
- Novel target for inflammatory modulation
- Oral administration
- Small molecules
- Strong intellectual property
|
|
|
|
|
|
